Q32 Bio Inc. Announces Executive Appointments: CMO and Chief Development Officer

What Happened
Q32 Bio Inc. announced on September 14, 2026 (filed on Form 8‑K), the appointments of José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. The company furnished a press release about these executive hires (Exhibit 99.1) and disclosed the news under Regulation FD (Item 7.01) and Other Events (Item 8.01).

Key Details

• Appointment date: September 14, 2026 (8‑K filing).
• José Trevejo, M.D., Ph.D.: most recently Chief Medical Officer & Head of Clinical Pipeline Strategy at Enveda Therapeutics (July 2024–Sept 2026); prior CMO at Tarsus Pharmaceuticals (Feb 2022–Feb 2024); Chief Development Officer at Rocket Pharmaceuticals (Oct 2020–Feb 2022). M.D./Ph.D. from the Cornell‑Rockefeller‑Sloan Kettering Tri‑Institutional program; residency and specialty training at Brigham and Women’s Hospital and Beth Israel Deaconess (Harvard affiliates).
• Ellie Hershberger, Pharm.D.: most recently a consultant at EMH Consulting LLC (Jan 2023–Sept 2026); previously Chief Development Officer at Adagio Therapeutics (now Invivyd) (June 2020–Jan 2023), where she led advancement of a lead monoclonal antibody through IND‑enabling to Phase 3. Pharm.D. from Ferris State University; research fellowship in PK/PD at Wayne State University.

Why It Matters
These hires add senior clinical and development leadership with recent experience advancing candidates through late‑stage development and regulatory interactions. For investors, stronger commercial and clinical development leadership can be relevant to the company’s ability to advance its pipeline, manage regulatory strategy, and prepare programs for potential late‑stage trials or approvals. The filing is a disclosure of executive changes—not a financial statement—so there are no reported financial impacts or compensation details in this 8‑K.